Healthcare Industry News: Medline
News Release - April 28, 2008
Covalon's Antimicrobial Coating on Foley Catheters Reduces Infections to "Zero" in Six Month Hospital StudyMISSISSAUGA, ONTARIO--(Healthcare Sales & Marketing Network)--Apr 28, 2008 -- Covalon Technologies Ltd. (the "Corporation" or "Covalon") (CDNX:COV.V ) announces that its antimicrobial silver coating on Foley catheters, sold by Medline Industries, has eliminated the incidence of nosocomial catheter-associated urinary tract infections ("CAUTI") during a six-month study at a rehabilitation hospital in northern Arkansas.
A study by St. Vincent Rehabilitation Hospital in Sherwood Arkansas, comparing infection rates using uncoated Foley catheters and Foley catheters coated with Covalon's antimicrobial ionic silver coating was recently published in the April issue of the Society of Urological Nurses and Associates.
The study compared numbers and rates of CAUTIs from data they gathered during two periods. The first was a four-month period in 2006 using a standard latex catheter. The second was a six-month period using the catheters coated with Covalon's antimicrobial silver coating. Authors Jackie Kassler, RN and Josh Barnett, RN, CRRN of St. Vincent's Rehabilitation Hospital in Sherwood, Ark. discovered ten nosocomial catheter-associated urinary tract infections during the four-month period using the standard latex catheters. During the six-months of testing using Covalon's silver-coated catheters, the hospital found "no" nosocomial catheter-associated urinary tract infections.
In the US the cost of treating a catheter associated infection is estimated between $35,000 and $56,000 per patient. The annual cost of caring for patients with urinary tract infections in the U.S. is up to $2.6 billion. According to the CDC, CAUTIs represent almost 40% of all health-care-acquired infections.
Beginning October 1, 2008, the Centers for Medicare & Medicated Services will cease reimbursement for the care and treatment of CAUTI acquired during a hospital stay. Consequently, in the interest of reducing costs, it would be in the best interests of the hospital and patient to prevent CAUTI by using Covalon's silver-coated Foley catheter.
William Jackson, Chief Business Officer stated "this great news should have a positive impact on our commercialization efforts for the coating on other devices". Covalon has also developed an antimicrobial and low-thrombogenic coating that is being developed to on a wide variety of in-dwelling, blood contacting devices for venous access catheters. The coating should reduce the incidence of hospital acquired infection as well as reducing thrombogenecity. Effective antimicrobial and low-thrombogenic coated catheters for venous access may reduce infection and thrombus formation thus improving patient outcome. Antimicrobial venous access catheters ("CVCs") are expected to experience a growth rate approximately 5-fold greater than that of un-coated CVCs. It is estimated that by 2009, sixty-nine percent (69%) of all CVCs used will be antimicrobial (Frost and Sullivan, U.S. Antimicrobial Devices Markets, 2003). Hospital-acquired infections affect approximately 2 million people in the United States each year, and cost over $11 billion to the healthcare system (Frost and Sullivan, U.S. Antimicrobial Coating Markets, 2006). The total antimicrobial catheters market is projected to attain revenues of US $ 375 million by 2009 (Frost and Sullivan 2006).
Covalon Technologies Ltd. is a company with advanced medical products that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings. Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility, and microbial attachment.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. Management assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
Source: Covalon Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.